• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23675 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2002     HAYES, Inc. Transilluminated powered phlebectomy for symptomatic varicose veins
2004     National Institute for Health and Care Excellence (NICE) Transilluminated powered phlebectomy for varicose veins. NICE interventional procedures guidance 37
2014     Agency for Healthcare Research and Quality (AHRQ) Transition care for children with special health needs
2011     Agency for Healthcare Research and Quality (AHRQ) Transition of care for acute stroke and myocardial infarction patients: from hospitalization to rehabilitation, recovery, and secondary prevention
2014     Agency for Healthcare Research and Quality (AHRQ) Transitional care interventions to prevent readmissions for people with heart failure
2014     NIHR Health Services and Delivery Research programme Transitions at the end of life for older adults - patient, carer and professional perspectives: a mixed-methods study
2022     Agency for Healthcare Research and Quality (AHRQ) Transitions of care from pediatric to adult services for children with special healthcare needs
2013     NIHR Health Services and Delivery Research programme Transitions to palliative care for older people in acute hospitals: a mixed-methods study
1996     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Transjugular intrahepatic porto-systemic shunt - systematic review, expert panel, primary research
2018     Penn Medicine Center for Evidence-based Practice (CEP) Transjugular Intrahepatic Portosystemic Shunts for Patients with Acute Variceal Bleeding
2013     National Institute for Health and Care Excellence (NICE) Translaryngeal tracheostomy. NICE interventional procedures guidance 462
2015     NIHR Health Services and Delivery Research programme Translation into British Sign Language and validation of the Strengths and Difficulties Questionnaire
1995     NIHR Health Technology Assessment programme Translation of Spanish report on routine pre-operative testing
2003     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Transluminal dilatation for symptomatic atheromatous stenosis of the carotid bifurcation
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transmission of infectious agents and risk of injury from patient transfer boards in healthcare settings: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Transmission of infectious agents from magazines, books, and toys in healthcare settings: clinical evidence and guidelines
2020     Penn Medicine Center for Evidence-based Practice (CEP) Transmission of respiratory infections via showers
2019     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
1999     Medical Services Advisory Committee (MSAC) Transmyocardial laser revascularisation
2009     National Institute for Health and Care Excellence (NICE) Transmyocardial laser revascularisation for refractory angina pectoris. NICE interventional procedures guidance 301
2002     HAYES, Inc. Transmyocardial laser revascularization
2000     Institute for Clinical Systems Improvement (ICSI) Transmyocardial laser therapy for severe refractory angina
1998     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Transmyocardial revascularisation by laser (systematic review, expert panel)
1998     University HealthSystem Consortium (UHC) Transmyocardial revascularization
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Transmyocardial revascularization for treatment of angina
1996     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Transmyocardial revascularization with laser
2011     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Transnasal oesophagoscopy (TNE)
1998     Institute of Technology Assessment (ITA) Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transobturator slings for urinary incontinence: clinical effectiveness and guidelines
2002     Medical Services Advisory Committee (MSAC) Transoesophageal echocardiography
2014     National Institute for Health and Care Excellence (NICE) Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. NICE interventional procedures guidance 484
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Transoral endoscopic thyroidectomy vestibular approach (TOETVA)
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Transoral robotic surgery: a review of clinical and cost-effectiveness
2024     NIHR Health Technology Assessment programme Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2022     Norwegian Institute of Public Health (NIPH) Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2025     National Institute for Health and Care Excellence (NICE) Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE interventional procedures guidance 798
2010     National Institute for Health and Care Excellence (NICE) Transperineal template biopsy and mapping of the prostate. NICE interventional procedures guidance 364
2002     HAYES, Inc. Transperineal ultrasound-guided brachytherapy for early-stage prostate cancer
2005     Technology Assessment Unit of the McGill University Health Centre (MUHC) Transplantation of allogeneic hematopoietic stem cells from unrelated donors in adult patients at the MUHC
2003     The Swedish Council on Health Technology Assessment (SBU) Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)
2001     The Swedish Council on Health Technology Assessment (SBU) Transplantation of stem cells from umbilical cord blood - early assessment briefs (Alert)
1994     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Transplantation with bone marrow not derived from HLA identical family donors for the treatment of adults and children with hemato-oncologic and congenital diseases - primary research
2002     Blue Cross Blue Shield Association (BCBS) Transplanting adult patients with hematopoietic stem cells from placental and umbilical cord blood
2012     NIHR Horizon Scanning Centre (NIHR HSC) Transportable haemodialysis machines for established renal failure
2007     New Zealand Health Technology Assessment (NZHTA) Transportation of emergency patients
2003     Institute for Clinical Effectiveness and Health Policy (IECS) Transpupillary thermotherapy
2002     NIHR Horizon Scanning Centre (NIHR HSC) Transpupillary thermotherapy for age-related macular degeneration - horizon scanning review
2004     National Institute for Health and Care Excellence (NICE) Transpupillary thermotherapy for age-related macular degeneration. NICE interventional procedures guidance 58
2002     HAYES, Inc. Transpupillary thermotherapy for choroidal tumors and macular degeneration
2011     Penn Medicine Center for Evidence-based Practice (CEP) Transradial access for cardiac catheterization
2013     HAYES, Inc. Transradial, transbrachial, and transulnar approaches for coronary angiography and intervention
1994     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Transurethral diathermy for benign prostatic hypertrophy: update -nonsystematic review
2003     National Institute for Health and Care Excellence (NICE) Transurethral electrovaporisation of the prostate. NICE interventional procedures guidance 14
2012     Medical Services Advisory Committee (MSAC) Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
2019     National Institute for Health and Care Excellence (NICE) Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer. NICE interventional procedures guidance 656
2000     HAYES, Inc. Transurethral microwave thermotherapy
2007     HAYES, Inc. Transurethral microwave thermotherapy
2000     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia
2002     Medical Services Advisory Committee (MSAC) TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia
2005     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
2001     ECRI Transurethral needle ablation [TUNA (R)] for benign prostatic hyperplasia
2001     HAYES, Inc. Transurethral needle ablation therapy
2007     HAYES, Inc. Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010     HAYES, Inc. Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2018     National Institute for Health and Care Excellence (NICE) Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 625
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2021     National Institute for Health and Care Excellence (NICE) Transvaginal laser therapy for stress urinary incontinence. NICE interventional procedures guidance 696
2021     National Institute for Health and Care Excellence (NICE) Transvaginal laser therapy for urogenital atrophy. NICE interventional procedures guidance 697
2017     National Institute for Health and Care Excellence (NICE) Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. NICE interventional procedures guidance 599
2011     HAYES, Inc. Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2023     National Institute for Health and Care Excellence (NICE) Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2016     NIHR Health Technology Assessment programme TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2004     HAYES, Inc. Trastuzumab (Herceptin (R)) for breast cancer
2007     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for advanced gastric cancer
2007     HAYES, Inc. Trastuzumab (Herceptin) for early breast cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2010     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2001     The Swedish Council on Health Technology Assessment (SBU) Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2007     HAYES, Inc. Trastuzumab (Herceptin) for metastatic cancer
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2006     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®)
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2003     ECRI Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2005     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2021     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2013     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2020     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2017     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Trastuzumab for breast cancer treatment
2006     Quality Improvement Scotland (NHS QIS ) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer